ArticleBMC endocrine disorders2026
Associations of complement proteins and immunoglobulins with cognitive impairment in type 2 diabetes mellitus: a cross-sectional study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a global health concern associated with an increased risk of cognitive impairment. While the complement system and immunoglobulins, crucial components of the immune system, have been implicated in the pathogenesis of both T2DM and cognitive decline, their specific clinical associations remain unclear. This study aims to investigate the association between inflammatory markers, specific complement proteins, immunoglobulins, and cognitive impairment in T2DM patients.
methodsA cross-sectional study was conducted involving 242 participants aged over 40 years from the First Hospital of Hebei Medical University between March 2022 and April 2023. Participants were divided into the control (n = 120), T2DM (n = 45), and T2DM with cognitive impairment (T2DM&CI) (n = 77) groups. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Blood samples were analyzed for fasting blood glucose, lipid profiles, complement proteins, and immunoglobulins. Statistical analyses included non-parametric tests, receiver operating characteristic (ROC) curve analysis, and linear and logistic regressions adjusted for covariates (age and gender).
resultsSignificant differences were observed among the groups in cognitive function scores, blood glucose, lipid levels, and inflammatory markers, complement proteins, and immunoglobulins. The T2DM & CI group exhibited lower MoCA scores and higher total cholesterol (TC), complement factor B (CFB), and immunoglobulin E (IgE) levels compared to the T2DM group. Correlation analyses revealed that elevated CFB and IgA were negatively correlated with cognitive function, whereas IgM showed a positive correlation. Following covariate adjustment, CFB remained independently associated with the presence of cognitive impairment in T2DM patients.
conclusionCognitive impairment in T2DM is significantly associated with altered immune-inflammatory profiles, specifically alternative complement pathway activation (elevated CFB) and specific immunoglobulin shifts (increased IgA, decreased IgM). CFB represents a promising potential biomarker for the early identification of cognitive risk in T2DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.